Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GNTbm-TKI
- Development stage
- Preclinical
- Lead developer
- GNT Biotech & Medicals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
GNTbm-TKI is a novel, orally administered **small molecule multi-tyrosine kinase inhibitor** with *potent immune-regulatory activity*, developed independently by Great Novel Therapeutics Biotech & Medicals Corporation (GNTbm). Its principal mechanism is the selective inhibition of multiple receptor tyrosine kinases: TYRO3, AXL, c-MER, BTK, ROS1, NTRK2, VEGFR2, and MET. GNTbm-TKI demonstrates strong immunomodulatory and tumor microenvironment (TME) remodeling capabilities. In preclinical models, it induces immune activation within tumors, suppresses tumor proliferation, invasion, and metastasis, inhibits angiogenesis, and is uniquely effective at transforming 'cold' tumors into 'hot' tumors when combined with HDAC inhibitors, immune checkpoint inhibitors (ICI), or anti-PD-1/VEGF bispecific antibodies. Its primary applications are: - Monotherapy for advanced neuroendocrine tumors - Combination therapy for a variety of advanced solid tumors, notably aiming to address unmet needs in tumors with immunologically cold TMEs GNTbm-TKI is currently in preclinical development, with plans to enter Phase I trials as an oral agent for cancer immunotherapy, expected around 2027[1][2][7].
- Brand names
- GNTbm-TKI
- Other names
- GNTbm-TKI
02
Targets
AXL (AXL receptor tyrosine kinase)BTK (Bruton tyrosine kinase)MET (Mesenchymal-epithelial transition factor receptor)NTRK2 (Tropomyosin-related kinase receptor type B)ROS1 (Proto-oncogene tyrosine-protein kinase ROS)VEGFR2 (Vascular endothelial growth factor receptor 2)MERTK (MER proto-oncogene, tyrosine kinase)TYRO3 (TYRO3 protein tyrosine kinase)
Beyond the preview
Go deeper on GNTbm-TKI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GNTbm-TKI.